Search Results
Jul 18, 2026, 14:55 ET REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting
com 1Singer MA, et al. Ophthalmology. 2012;119(6):1175-83. 2 Silva R, et al. Ophthalmology. 2012;120,130-39.; 3Maguire MG, et al. Ophthalmology. 2016;123, 1751-61. 4Khanani A, et al. Ophthalmology. 2019;4(2):122-33. 5Ciulla T, et al. Ophthalmology.
More news about: REGENXBIO Inc.
Jul 17, 2026, 08:50 ET Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time
randomized 36 patients 2-to-1 active to placebo at 20 mg or 2 mg, given as two intramuscular doses three weeks apart. Patients entered with an average baseline HAM-A of 22 and remained symptomatic despite ongoing standard-of-care antidepressant therapy. The 20 mg dose produced an average improvement of more than
More news about: USA News Group
Jul 17, 2026, 07:00 ET DIMERIX EXPANDS PIPELINE WITH ACQUISITION OF PHASE 2 READY ASSET FOR ACUTE KIDNEY INJURY
received the drug candidate. The trial successfully demonstrated DMX-652 was safe and well tolerated in single doses of up to 200mg a day and multiple doses of up to 100mg a day for 14 days, with a promising pharmacokinetic profile.Building a focused, rare kidney disease portfolioThe
More news about: Dimerix Limited
Jul 16, 2026, 10:01 ET NASH Treatment Market Accelerates as Rezdiffra and Wegovy Establish Fibrosis-Defined Drug Pathways, Says Strategic Market Research
2 SYNERGY-NASH study, MASH resolution without worsening fibrosis occurred in 44%, 56%, and 62% of patients receiving tirzepatide doses of 5 mg, 10 mg, and 15 mg, respectively, compared with 10% receiving placebo.Akero Therapeutics is advancing efruxifermin through Phase 3 studies for noncirrhotic
More news about: Strategic Market Research LLP
Jul 16, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Erasca, Inc. of Class Action Lawsuit and Upcoming Deadlines - ERAS
after market hours on April 27, 2026, Erasca reported preliminary Phase 1 clinical data for ERAS-0015 and disclosing that one patient that received 24 mg of ERAS-0015 had died approximately a month after starting ERAS-0015. The patient was classified as a "Grade 3 TRAE of pneumonitis" that "progressed
More news about: Pomerantz LLP
Jul 16, 2026, 05:00 ET BrainMD Launches Happy Saffron Plus® Gummies, Making Its Beloved Brain Health Formula Easier Than Ever To Enjoy Daily
formula:affron® Saffron Extract A clinically studied saffron extract shown to support positive mood and emotional wellness. Each serving delivers 28 mg of affron®, the same dose used in clinical research.*Longvida® Optimized Curcumin A patented form of curcumin developed for enhanced
More news about: BrainMD
Jul 15, 2026, 20:00 ET ERAS INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Erasca, Inc. Investors with Substantial Losses Have Opportunity to Lead Erasca Class Action Lawsuit
after market close on April 27, 2026, Erasca reported preliminary Phase I clinical data for ERAS-0015 and disclosed that one patient who received 24 mg of ERAS-0015 had died approximately one month after starting ERAS-0015. Erasca allegedly further disclosed that comparisons between ERAS-0015
More news about: Robbins Geller Rudman & Dowd LLP
Jul 15, 2026, 15:37 ET The Commander-in-Chief of the Military Order of the World Wars, Lt Col David J. Worley, USAF (Retired), will present the Distinguished Service Award to Major General Patrick Henry Brady, United States Army (Retired)
Army veteran who was awarded the Medal of Honor for a series of extraordinary helicopter rescue missions during the Vietnam War. On that fateful day, MG Brady utilized three different helicopters to evacuate 51 critically wounded soldiers from multiple enemy-engaged ("hot") landing zones and a minefield.
More news about: The Military Order of the World Wars
Jul 15, 2026, 09:00 ET Future Nutra Foundation Reveals Most Hemp-Derived THC Beverages Miss the Mark on Potency
underdosing, including examples where measured THC content was less than one quarter of the labeled amount. In one case, a beverage labeled at 5 mg Δ9-THC contained just 0.19 mg (only 3.8% of the claimed dose). Several other products fell in the 20-40% range of their stated THC content, meaning consumers may be
More news about: Future Nutra Foundation
Jul 15, 2026, 08:00 ET Terrabis Launches Jelly Roll Shots and Mind Melt Vapes in Missouri
new format. Available in Watermelon, Blue Razz and Green Apple, the shots are nano-emulsified for a rapid-onset experience and are available in 25mg and 100mg strengths.The new Jelly Roll Shots lineup features some of Jelly Roll's most popular flavors in a compact, ready-to-enjoy infused beverage
More news about: Terrabis
Jul 15, 2026, 06:00 ET 歌禮選定同類首創口服小分子GIPR激動劑ASC48和口服小分子GLP-1R激動劑ASC30的固定劑量復方制劑進行臨床開發
FDC（GLP-1R/GIPR激動劑）2 mg/kg ASC30 和 5 mg/kg ASC48口服, 每日一次
More news about: 歌禮製藥有限公司
Jul 15, 2026, 06:00 ET Ascletis Selects for Clinical Development a Fixed-Dose Combination of First-in-Class Oral Small Molecule GIPR Agonist, ASC48, and Oral Small Molecule GLP-1R Agonist, ASC30
(GLP-1R/GIPR agonist)2 mg/kg ASC30 and 5 mg/kg ASC48PO, QD
More news about: Ascletis Pharma Inc.
Jul 15, 2026, 04:25 ET World of Hyatt Expands HYROX Collaboration to India
MumbaiHyatt Centric JanakpuriGrand Hyatt MumbaiHyatt Regency DelhiHyatt Centric Hebbal BengaluruHyatt Centric MG Road BangaloreHyatt Regency AhmedabadGrand Hyatt GurgaonHyatt Place GurgaonLearn more and see full terms and
More news about: Hyatt Hotels India & Southwest Asia
Jul 15, 2026, 00:30 ET Making Strides in Cardiac Healthcare at Zydus Hospitals, Gujarat
patient's anatomy," Dr. Bhavesh Roy said. "What made this case particularly challenging was that the patient was on dialysis, with a creatinine of 3 mg/dL and haemoglobin of 7 g/dL," he added. This meant the team had to manage significant renal impairment and anaemia alongside the procedure, and despite
More news about: Zydus Hospitals and Healthcare Research Private Limited
Jul 14, 2026, 13:56 ET Spinogenix Reports Positive Data on Alzheimer's Patients Who Continued Treatment With Tazbentetol For Up To 84 Weeks
of a 4-week double-blind placebo-controlled period in which participants received 150mg or 300mg tazbentetol QD (or placebo), followed by an open label extension (OLE) period during which all participants received 300mg tazbentetol through 24 weeks.Key findings from the Phase 2a trial were presented
More news about: Spinogenix
Jul 14, 2026, 11:08 ET B. Braun Announces Approval and Commercialization of First Generic Sugammadex Injection in the U.S. Market
infusion therapy and pharmaceutical manufacturing, announced the U.S. Food and Drug Administration (FDA) approval of Sugammadex Injection, 200 mg/2 mL (100 mg/mL), AP-rated generic BRIDION®1* (Sugammadex Injection) in the U.S. market. The product, which will be available July 28, 2026 in a single-dose
More news about: B. Braun Medical Inc.
Jul 14, 2026, 08:34 ET Slumber Launches a Complete Sleep System: Magnesium Glycinate and Upgraded Deep Zzzs Formulas
Zzzs, raising CBD to 40mg, CBN to 15mg, and THC to 5mg per serving to further cut nighttime awakenings and extend total sleep.For customers who want Slumber's efficacy without THC, the brand also launched THC-free Deep Zzzs, combining 40mg broad-spectrum CBD, 25mg CBN, and 250mg of the clinically
More news about: Slumber Sleep Inc.
Jul 14, 2026, 08:00 ET Apnimed Announces FDA Acceptance of New Drug Application for AD109, An Investigational Oral Pill to Treat Adults with Obstructive Sleep Apnea (OSA)
that the U.S. Food and Drug Administration ("FDA") has accepted for review the New Drug Application ("NDA") filing of AD109 (aroxybutynin 2.3 mg/atomoxetine 75 mg) for the treatment of adults with obstructive sleep apnea ("OSA"). The FDA has assigned a Prescription Drug User Fee Act ("PDUFA") target action
More news about: Apnimed, Inc.
Jul 14, 2026, 07:30 ET Illuminare Biotechnologies Appoints Veteran Biopharmaceutical Leader as New CEO
conducted at Memorial Sloan Kettering Cancer Center in Manhattan and demonstrated safety and tolerability, with a clinically effective dose reached at 3.0 mg/kg, improving visualization of nerves. I look forward to working closely with our team, the Board, and our scientific collaborators to accelerate our
More news about: Illuminare Biotechnologies
Jul 13, 2026, 22:42 ET FDA approves Leqembi Iqlik® (lecanemab-irmb) subcutaneous injection as a starting dose for early Alzheimer's disease
start of treatment. For initiation, the approved regimen is 500 mg once weekly, delivered as two 250 mg injections, each administered in approximately 15 seconds.Leqembi Iqlik is already approved for maintenance dosing in the US at 360 mg once weekly, once 18 months of IV or subcutaneous treatment
More news about: BioArctic
Jul 13, 2026, 22:37 ET FDA approves Leqembi Iqlik® (lecanemab-irmb) subcutaneous injection as a starting dose for early Alzheimer's disease
start of treatment. For initiation, the approved regimen is 500 mg once weekly, delivered as two 250 mg injections, each administered in approximately 15 seconds.Leqembi Iqlik is already approved for maintenance dosing in the US at 360 mg once weekly, once 18 months of IV or subcutaneous treatment
More news about: BioArctic
Jul 13, 2026, 17:36 ET FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease
from the start of treatment. For initiation, the approved regimen is 500 mg given once weekly as two 250 mg injections, each delivered in approximately 15 seconds. LEQEMBI IQLIK may also be used for maintenance dosing at 360 mg once weekly after 18 months of IV or subcutaneous treatment. Throughout the
More news about: Eisai Inc.
Jul 13, 2026, 08:45 ET A Clean Caffeine Alternative for the Open Road
help millions of Americans travel this summer with minimal bathroom breaks.Buzz Bomb is an innovative, everyday energy brand that delivers 50 mg of fast-acting caffeine in the form of non-liquid, single-serve sachets. The caffeine comes from non-GMO sources, making it an convenient, rapid, and
More news about: Buzz Bomb
Jul 13, 2026, 08:41 ET Buzz Bomb Is Boosting Energy (While Giving the Digestive System a Break)
Buzz Bomb's innovative sachets are a form of caffeine like never experienced before. Each non-liquid sachet contains 50 mg of caffeine sourced directly from non-GMO sources. They come in delicious flavors and go directly under the tongue for fast-acting absorption that gets
More news about: Buzz Bomb
Jul 13, 2026, 08:35 ET A Longhorn in Dallas Has Been Calling the Knockout Rounds All Tournament. On Thursday, He Picks the Winner of the Final. Live.
Dallas-born beverage enhancer brand on a mission to upgrade the drink you already have. Drizz Unflavored Energy Drops turn any drink into an energy drink: 65mg of caffeine from green tea extract with L-theanine, 15 servings in a 2oz bottle, zero sugar. Drizz won a 2025 Walmart Golden Ticket with its Mixer Drops
More news about: Drizz